COMMUNIQUÉS West-GlobeNewswire

FDA Approves Sanofi's Admelog® (insulin lispro injection)
11/12/2017
Press Release Source: Sanofi (EURONEXT: SAN) (NYSE: SNY) FDA Approves Sanofi's Admelog ® (insulin lispro injection) First FDA-approved follow-on mealtime insulin Admelog (insulin lispro injection) 100 Units/mL will be [...]
La FDA approuve l'insuline lispro injectable Admelog® de Sanofi
11/12/2017
Communiqué de presse Source : Sanofi (EURONEXT: SAN) (NYSE: SNY) La FDA approuve l'insuline lispro injectable Admelog ® de Sanofi Première insuline prandiale « follow-on » [1] approuvée par la FDA Admelog (insuline [...]
U.S. Army Dental Corps Veteran Honored by the American College of Prosthodontists
11/12/2017
Chicago, Dec. 11, 2017 (GLOBE NEWSWIRE) -- Ronald D. Woody, DDS, FACP , was honored with the Major General Bill B. Lefler Federal Services Award at the Annual Awards & President’s Dinner during the American College [...]
RedHawk Completes EcoGen Share Transfer Agreement
11/12/2017
LAFAYETTE, La., Dec. 11, 2017 (GLOBE NEWSWIRE) -- RedHawk Holdings Corp. (OTCQB:IDNG) (“RedHawk” or the “Company”) announced today that along with its wholly-owned subsidiary, RedHawk Pharma UK Limited (“RedHawk Pharma [...]
Almirall and Athenex announce strategic partnership for the treatment of actinic keratosis
11/12/2017
Almirall and Athenex have entered into a strategic partnership to develop and commercialize KX2-391 in the United States and Europe KX2-391 is a first-in-class topical treatment currently in Phase III development that [...]
Ossur Hf : Transactions in relation to share buyback program
11/12/2017
Announcement from Össur hf. No. 86/2017 Reykjavík, 11 December 2017 On 15 August 2017, Össur hf. initiated a share buy-back program, see Company announcement no. 59/2017. The purpose of the share buyback program is to [...]
Novartis drug crizanlizumab shown to prolong time to patients' first sickle cell pain crisis in subgroup analysis of SUSTAIN study
11/12/2017
Investigational therapy crizanlizumab (SEG101, formerly SelG1) approximately doubled the time to first on-treatment sickle cell pain crisis, according to new subgroup analysis of Phase II SUSTAIN data Results were [...]
Phase 1 Data for Flotetuzumab, MacroGenics’ CD123 x CD3 DART® Molecule, Presented at 59th Annual ASH Meeting
11/12/2017
Encouraging initial anti-leukemic activity with durable responses and acceptable tolerability observed in dose expansion cohort Data supports combination with MGA012 (anti-PD-1) to potentially enhance anti-leukemic [...]
Thetis Builds Scientific Advisory Board to Guide Development of Immuno-Resolving Therapies for IBD
11/12/2017
BRANFORD, Conn., Dec. 11, 2017 (GLOBE NEWSWIRE) -- Thetis Pharmaceuticals LLC (“Thetis”), a biopharmaceutical company developing oral, “immuno-resolving” therapies to treat inflammatory bowel disease (IBD), announced [...]
Reporting of transactions with ALK-Abelló A/S' B-shares and associated securities by person closely associated with person discharging managerial responsibly
11/12/2017
Copenhagen, 2017-12-11 16:29 CET (GLOBE NEWSWIRE) -- With reference to company announcement no. 35/2017 and no. 36/2017 regarding offering, pricing and completing of the offering of new shares in ALK-Abelló A/S, company [...]
Novo Nordisk A/S - Share repurchase programme
11/12/2017
Bagsværd, Denmark, 11 December 2017 - On 1 November 2017, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No. 596/2014 of the European Parliament and Council of 16 April [...]
Kura Oncology Identifies Potential Biomarkers of Activity for Lead Candidate Tipifarnib in Bone Marrow Cancers
11/12/2017
CXCR4/CXCR2 expression ratio and bone marrow homing of myeloid cells identified as potential markers for tipifarnib in MDS, AML and CMML CXCL12/CXCR4 pathway a potential therapeutic target of farnesyl transferase [...]
Bellicum Pharmaceuticals Announces Presentations of its Controllable Switch Technology Platform at the American Society of Hematology 2017 Annual Meeting
11/12/2017
ATLANTA, Dec. 11, 2017 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (NASDAQ: BLCM ), a leader in developing novel, controllable cellular immunotherapies for cancers and orphan inherited blood disorders, today [...]
BeiGene Presents Initial Phase 1b Data for BTK Inhibitor Zanubrutinib (BGB-3111) Combined with PD-1 Antibody Tislelizumab (BGB-A317) at the 59th American Society of Hematology Annual Meeting
11/12/2017
CAMBRIDGE, Mass. and BEIJING, China, Dec. 11, 2017 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ: BGNE ), a commercial-stage biopharmaceutical company focused on developing and commercializing innovative molecularly [...]
Atara Biotherapeutics Announces Updated Positive Interim Results from Multicenter Expanded Access Study of tabelecleucel in Patients with Rituximab-Refractory Epstein-Barr Virus (EBV) Associated Post-Transplant Lymphoproliferative Disorder (PTLD)
11/12/2017
SOUTH SAN FRANCISCO, Calif., Dec. 11, 2017 (GLOBE NEWSWIRE) -- Atara Biotherapeutics, Inc. (Nasdaq: ATRA ), a leading off-the-shelf T-cell immunotherapy company developing novel treatments for patients with cancer, [...]
Clinical Data for eFFECTOR Therapeutics’ Lead Candidate eFT508 Demonstrates Clinical Activity, Well-Tolerated Safety Profile
11/12/2017
Preclinical Data Shows Potential of eFT226 in B-cell Malignancies Data to be presented at the ASH 59 th Annual Meeting and Exposition SAN DIEGO, Dec. 11, 2017 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics, Inc., a leader in [...]
BioStem Technologies Inc. Announces a Pre-Clinical Study of BSEM17-115 at University of Miami
11/12/2017
Pompano Beach, FL, Dec. 11, 2017 (GLOBE NEWSWIRE) -- BioStem Technologies, Inc. (OTC PINK: BSEM) (“BSEM” or “Company”), in collaboration with the University of Miami’s Department of Dermatology and Cutaneous Surgery [...]
FRDJ salue la décision de l’ARC de revoir les refus des demandes pour le diabète
11/12/2017
TORONTO, 11 déc. 2017 (GLOBE NEWSWIRE) -- Les plus de 300 000 Canadiens et leur famille qui vivent avec le diabète de type 1 (DT1) au pays se réjouissent de l’annonce faite aujourd’hui du gouvernement du Canada et de l’ [...]
Salvis Lapins Will Remain of Olainfarm’s Management Board
11/12/2017
Olaine, 2017-12-11 15:20 CET (GLOBE NEWSWIRE) -- “I have very strong ties with Olainfarm. They have matured during more than a decade, during which we had our reasons for celebrations and we have coped with quite a few [...]

Pages